RRBI:NASDAQRed River Bancshares, Inc. Analysis
Data as of 2026-06-13 - not real-time
$92.70
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Red River Bancshares is trading at a price that sits comfortably above its 20‑day and 50‑day moving averages, with a bullish MACD histogram reinforcing short‑term momentum. The stock’s price‑to‑earnings multiple of roughly 14 is well below the regional banking industry average of 17, suggesting a valuation edge, while the price‑to‑book ratio of 1.6 aligns with sector norms. Strong profitability metrics – operating margins near 48% and a net profit margin above 35% – together with a solid return on equity around 12% underscore the company’s efficient earnings engine. A low beta of ~0.7 indicates muted sensitivity to broader market swings, yet the 30‑day volatility of over 23% signals price swings that could surprise traders. The balance sheet is exceptionally clean, featuring ample cash reserves exceeding $210 million and virtually no debt, which cushions credit risk. Dividend sustainability looks robust, with a payout ratio just above 10% and a modest yield of 0.86%, offering a modest income stream without eroding cash flow. Recent corporate actions – a board refresh and the declaration of a quarterly cash dividend – add a layer of stability but no material operational catalyst.
Given the modest upside to analyst target prices (~7% upside) and a DCF‑derived fair value that still sits above current levels, the stock appears undervalued with room for price appreciation, especially if the broader market sentiment remains in the “extreme greed” zone. Investors should weigh the attractive valuation and strong fundamentals against the sector’s inherent interest‑rate and credit sensitivities, and consider positioning for incremental gains while monitoring resistance around $94.5.
Given the modest upside to analyst target prices (~7% upside) and a DCF‑derived fair value that still sits above current levels, the stock appears undervalued with room for price appreciation, especially if the broader market sentiment remains in the “extreme greed” zone. Investors should weigh the attractive valuation and strong fundamentals against the sector’s inherent interest‑rate and credit sensitivities, and consider positioning for incremental gains while monitoring resistance around $94.5.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish MACD and price above short‑term moving averages
- Proximity to resistance level near $94.5
- Increasing volume supporting current price action
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervalued relative to peers (PE 13.9 vs industry 16.8)
- Strong profitability and low payout ratio sustaining dividend
- Analyst price target indicating ~7% upside
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Robust cash position and negligible debt
- Consistent earnings growth and high operating margins
- Durable dividend with ample coverage
Key Metrics & Analysis
Financial Health
Revenue Growth9.40%
Profit Margin35.23%
P/E Ratio13.9
ROE12.56%
ROA1.36%
P/B Ratio1.6
Op. Cash Flow$47.8M
Industry P/E16.8
Technical Analysis
TrendNeutral
RSI55.7
Support$87.37
Resistance$94.47
MA 20$90.80
MA 50$91.87
MA 200$78.95
MACDBullish
VolumeIncreasing
Fear & Greed Index89.86
Valuation
Fair Value$131.89
Target Price$99.50
Upside/Downside7.34%
GradeUndervalued
TypeBlend
Dividend Yield0.86%
Risk Assessment
Beta0.67
Volatility23.04%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.